必思添改善慢性阻塞性肺疾病反复下呼吸道感染

目的 :观察必思添改善慢性阻塞性肺疾病反复下呼吸道感染的疗效。方法 :慢性阻塞性肺疾病反复下呼吸道急性感染的病人 64例 ,随机分成必思添加抗生素治疗组 33例 (男性 2 5例 ,女性 8例 ,年龄 70a±s13a) ,服抗生素基础上加服必思添mo1,2mg·d- 1,mo 2～ 3,1mg·d- 1,每月服 8d ,单服抗生素治疗为对照组 31例 (男性 2 5例 ,女性 6例 ,年龄 72a± 12a)。观察随访 2组病人用药后 6mo内临床状况。结果 :治疗组病人下呼吸道急性感染发作次数显著减少 ,感染持续时间明显缩短 ,抗生素的用量显著减少 ,且无副作用。结论 :必思添是改善慢性阻塞性肺疾病下呼吸道感染的安全和有效药物

Clinical study of Biostim to improvation of recurrent lower respiratory tract infection in obstructive lung diseases

AIM: To observe the effects of Biostim in prevention and improvation of recurrent lower respiratory tract infection in chronic obstructive pulmonary diseases (COPD). METHODS: Sixtyfour patients with COPD were randomly divided into 2 groups: the treated group (33 patients, M 25, F 8; age 70 a±s13 a) received Biostim and antibiotics, Biostim treated 3 mo, mo 1, 2 mg·d -1 , po, for 8 d, mo 2～3, 1 mg·d -1 , po for 8 d; the control group (31 patients, M 25, F 6; age 72 a ±12 a) received antibiotics therapy only. Two groups were similar with anatibiotics for 7 d to 10 d. All patients were follow up for 6 mo. RESULTS: In treated group, times of lower repiratory tract infection and dosage of antibiotics were obviousely decrease. Infection duration were shorten. There were no adverse reactions. CONCLUSION: Biostim is an effective and saft drug in improvation of repeat lower respiratory tract infection in COPD.